Cerenis Therapeutics receives €2.5 million investment from French government through OSEO

12-Feb-2009 - France

Cerenis Therapeutics SA, a privately held pharmaceutical company, announced that it has received a €2.5 million investment to finance ongoing clinical development of its portfolio of HDL-related products for the treatment of cardiovascular and metabolic diseases. The funds were granted by OSEO, a French public holding company that provides financial support to promising French companies.

The financing will support continued development of the company's CER-001 program (recombinant HDL). In 2008 the company initiated preclinical studies to enable an Investigational New Drug (IND) application for this product candidate.

"This new source of funding will support our efforts to advance Cerenis HDL through the IND process and onto clinical development." said Jean-Louis Dasseux, Ph.D., M.B.A., president and CEO of Cerenis. "We are grateful to OSEO for its generous support of our efforts to bring this promising product candidate to market."

Other news from the department business & finance

More news from our other portals

All FT-IR spectrometer manufacturers at a glance